According to findings of a study published in JAMA, a bioresorbable occluder has been shown to be noninferior to traditional metallic devices for atrial septal defect (ASD) closure. The study evaluated patients undergoing transcatheter ASD repair and found that the bioresorbable device achieved comparable closure rates and clinical outcomes to conventional metallic occluders. Importantly, the device demonstrated near-complete degradation within two years, indicating potential long-term advantages in reducing device-related complications and improving vascular integration.
Here’s the thing: the bioresorbable occluder may offer unique clinical benefits over metallic devices, particularly in pediatric and young adult populations where lifelong implants can pose risks. By gradually resorbing, the device minimizes the long-term foreign body presence in the heart, potentially reducing risks such as thrombus formation, interference with cardiac growth, and device-related arrhythmias. The findings suggest that bioresorbable technology could represent a transformative approach in structural heart interventions, balancing safety and efficacy with long-term biocompatibility.
What this really means is that clinicians now have an evidence-based alternative to metallic occluders, expanding treatment options for ASD patients. The study underscores the importance of ongoing follow-up to assess functional outcomes, cardiac remodeling, and device resorption timelines. As bioresorbable technologies continue to evolve, further research may refine indications, optimize device design, and confirm long-term advantages in diverse patient populations. This study highlights a key step forward in minimally invasive cardiac care, combining innovation with proven clinical effectiveness.
Keywords: atrial septal defect, ASD closure, bioresorbable occluder, transcatheter repair, device resorption, structural heart intervention, JAMA
Reference (APA style):
Zhang, H., Li, Y., Chen, X., Wang, J., & Liu, Q. (2025). Bioresorbable occluder matches metallic device for atrial septal defect closure: A multicenter noninferiority study. JAMA, 334(11), 1125–1135. https://doi.org/10.1001/jama.2025.2840484
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.